TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Escalated Dose of Irinotecan in mCRC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. 20 y/o ≦ Age ≦ 80y/o~2. Either metachronous or synchronous mCRC can be enrolled~3. Female patients need not ready to be pregnant or breastfeeding~4. No major underlying diseases (such as cardiovascular, cerebrovascular, malignant hypertension, kidney, liver and other major diseases)~5. mCRC be proven by pathologists or radiologists~6. Subjects are willing to sign an inform consent form~Exclusion Criteria:~* Patients who do not meet the including criteria or unwilling to participate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- UGT1A1 genotyping (6,6) (Type: EXPERIMENTAL): The investigators will escalate the dosage of irinotecan from 180mg/m2 to 260 mg/m2
- UGTA1T1 genotyping (6,7) (Type: EXPERIMENTAL): The investigators will escalate the dosage of irinotecan from 180mg/m2 to 240 mg/m2
- UGTA1T1 genotyping (7,7) (Type: EXPERIMENTAL): The investigators will escalate the dosage of irinotecan from 120mg/m2 to 180 mg/m2
- UGT1A1 non-genotyping (Type: EXPERIMENTAL): The investigators will maintain the dosage of irinotecan by 180mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 40 to ≤ 85 years of age~* History of clinically evident cardiovascular disease at high risk for a recurrent event~* Fasting low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL (≥ 1.8 mmol/L) ) or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (\> 2.6 mmol/L)~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~* New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction \< 30%~* Uncontrolled hypertension~* Uncontrolled or recurrent ventricular tachycardia~* Untreated hyperthyroidism or hypothyroidism~* Homozygous familial hypercholesterolemia~* LDL or plasma apheresis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
- Evolocumab (Type: EXPERIMENTAL): Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed stage I seminomatous germ cell tumor of the testis categorized as either classical or anaplastic~PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine less than 1.4 mg/dL Other: No concurrent or previously treated malignancy except successfully treated nonmelanoma skin cancer No medical condition or other factor that would preclude study~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: No more than 8 weeks since prior orchidectomy Prior inguino-pelvic or scrotal surgery allowed Must be treated with dog-leg field if randomized to radiotherapy If prior vasectomy, choice of fields is at the discretion of the clinician

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Men or women at least 18 years of age at time of screening.~* Having a diagnosis of CSU and the presence of symptoms for ≥6 months prior to the screening visit.~* Presence of itch and hives for ≥6 consecutive weeks at any time prior to the screening visit despite concurrent use of non-sedating H1-antihistamine treatment~* Patient must have been on an approved dose of non-sedating H1-antihistamine for CSU, and no other concomitant CSU treatment, for at least the 7 consecutive days immediately prior to the randomization visit and must document current use on the day of the randomization visit.~Key Exclusion Criteria:~* Patients having a clearly defined underlying etiology for chronic urticaria other than CSU including the following urticarias: acute, solar, cholinergic, heat, cold, aquagenic, delayed pressure or contact~* Patients with other skin disease associated with itch that could interfere with study outcomes and/or compromise the safety of the patient~* Patients with evidence of parasitic infection~* Patients with a history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~* Pregnant or nursing (lactating) women,~* Women of child-bearing potential, unless they are using effective methods of contraception during dosing of study treatment.~* Patients who are unable or unwilling to comply with study procedures, attend scheduled study visits, complete questionnaires and daily diaries, or who may otherwise be unable to comply with the study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- omalizumab 150mg (Type: EXPERIMENTAL): Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
- omalizumab 300mg (Type: EXPERIMENTAL): Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 40 to 85 years old, inclusive at screening~* Expected to be able to undergo all study procedures~* Other inclusion criteria apply~For Part B only:~* A diagnosis of PD, confirmed by a neurologist~* Hoehn \&Yahr Stage ≤ III at Screening~* Stable treatment of permitted antiparkinsonian medications from 30 days prior to first study drug administration or 60 days for MAO-B inhibitors, and expected to remain stable throughout the study~Exclusion Criteria:~* Clinically significant abnormalities, as judged by the investigator~* History of medical, neurological or psychiatric conditions which in the opinion of the investigator may compromise participant's safety or scientific value of the study~* Acute or chronic infection as judged by the investigator, for positive human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)~* History or evidence of an autoimmune disorder~* History of anergy.~* Participated/participating in any clinical trial with monoclonal antibodies or vaccines directed at aSyn~* Other exclusion criteria apply~For Part B only:~* Other known or suspected cause of Parkinsonism other than idiopathic PD~* History or evidence at Screening of PD-related freezing episodes, falls, or orthostatic hypotension~* Dopamine transporter single-photon emission computerized tomography scan (DaTscan) inconsistent with dopamine transporter deficit.~* Clinically significant neurological disease other than PD

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- UB-312 40 mcg (Type: EXPERIMENTAL): UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13
- UB-312 100 mcg (Type: EXPERIMENTAL): UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13
- UB-312 40/300 mcg (Type: EXPERIMENTAL): UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection
- UB-312 300 mcg (Type: EXPERIMENTAL): UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13
- UB-312 40/1000 mcg (Type: EXPERIMENTAL): UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection
- UB-312 1000 mcg (Type: EXPERIMENTAL): UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13
- UB-312 2000 mcg (Type: EXPERIMENTAL): UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by intramuscular injection at Weeks 1, 5 and 13
- UB-312 300/100 mcg (Type: EXPERIMENTAL): UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Oral Replacement in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index greater than or equal to 85% for age and sex~* Physician-diagnosed asthma~* Ongoing relationship with asthma provider responsible for asthma care~* Serum 25(OH) D level 10 ng/ml to less than 30 ng/ml at screening visit based on local laboratory test~* Ability to swallow pills similar in size to the vitamin D preparation to be used~* Signed consent form from parent, legal guardian or caregiver and signed assent from participant (as appropriate)~* Females of childbearing years must not be pregnant, must not be lactating and must agree to practice adequate birth control method~* Child and parent, legal guardian, or caregiver must speak English or Spanish~Exclusion Criteria:~* Known diseases of calcium metabolism or the parathyroid~* History of renal insufficiency or kidney stones~* Known liver failure or history of abnormal liver function tests~* History of Williams syndrome, sarcoidosis, or granulomatous disease~* Active tuberculosis~* Spot urine calcium/creatinine ration greater than 0.37 (calcium and creatinine measured in mg/ml). This can be repeated following adequate hydration~* Clinical evidence of rickets~* Taking supplemental vitamin D greater than equal to 1000 IU per day

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Part 1, Cohort 1 Vitamin D3 oral regimen (Type: EXPERIMENTAL): Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose
- Part 1, Cohort 2 Vitamin D3 oral regimen (Type: EXPERIMENTAL): Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose
- Part 1, Cohort 3 Vitamin D3 oral regimen (Type: EXPERIMENTAL): Vitamin D: 6000 IU daily dose
- Part 1, Cohort 4 Vitamin D3 oral regimen (Type: ACTIVE_COMPARATOR): Vitamin D: 600 IU daily dose
- Part 2, Cohort A Vitamin D3 oral regimen (Type: EXPERIMENTAL): Vitamin D: Single 50,000 IU loading dose + 8,000 IU daily doseD
- Part 2, Cohort B Vitamin D oral regimen (Type: ACTIVE_COMPARATOR): Vitamin D: 600 IU daily dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic Hypertrophic Cardiomyopathy patients~2. Abnormal Peak VO2~3. No significant LVOT obstruction at rest (gradient \< 30mmHg)~4. Sinus rhythm~Exclusion Criteria:~1. Abnormal LFT.~2. Concomitant use of amiodarone~3. Pre-existing evidence of peripheral neuropathy.~4. Women of childbearing potential.~5. Patients with ICD's will be excluded from the MR part of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* over or equal 22 years at screening~* approximately symmetrical moderate to severe nasolabial folds~* negative urine pregnancy test~* healthy skin~* willing to abstain from aesthetic or surgical procedures in the treatment area~* written informed consent~Exclusion Criteria:~* pregnant and/or lactating~* history of allergies or hypersensitivity to e.g. hyaluronic acid preparations~* tendency to keloid formation~* HIV positive~* presence of infectious, inflammatory or proliferative cancerous or pre-cancerous lesions~* herpes simplex in treatment area~* autoimmune or connective tissue disease, immunomodulating therapy~* uncontrolled diabetes or systemic diseases~* Facial plastic surgery, tissue augmentation~* implantation of facial dermal fillers within 12 months~* Skin of nasolabial region affected by aesthetic treatments~* Facial lipolysis~* Bariatric surgery within 12 months~* History of bleeding disorder~* Planned dental/oral surgery~* Any medical condition prohibiting the inclusion according to the investigator~* Previous enrollment~* Current participation in another clinical investigation within 30 days prior to enrollment~* Dependency of the subject to the investigation site

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment of device 1 on left side (Type: OTHER): Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF
- Treatment of device 1 on right side (Type: OTHER): Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Natural Food on Gut Microbiome and Phospholipid Spectrum of Immune Cells in COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and older;~2. Patients in rehabilitation after COVID-19;~3. Signed informed consent;~4. Presence of patient's history of COVID-19, reliably established by PCR+ /presence of IgG/ diagnosis of coronavirus pneumonia on Computer Tomography based on discharge from hospital or outpatient records.~Exclusion Criteria:~1. Chronic inflammatory bowel disease;~2. Gut microbiota transplantation;~3. Chronic pancreatic disease, period of exacerbation;~4. Liver cirrhosis, Metavir stage 3-4;~5. Any disease in the decompensation stage;~6. Neuralgic and psychological disorders that interfere with the study;~7. Cancer;~8. Non-transportable patients;~9. Patients who do not reside in Almaty;~10. Patients who have refused to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Main Group (Type: EXPERIMENTAL): Patients who had suffered from COVID-19 in the six months before the start of the study. Patients will receive Saumal (freeze-dried mare milk) for four weeks.
- Control Group (Type: NO_INTERVENTION): Patients who had suffered from COVID-19 in the six months before the start of the study. There will be no intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is determined to be hypertensive~Exclusion Criteria:~* Participant has a history of severe or symptomatic hypertension~* Participant has history of heart failure, rhythm disturbance or cardiomyopathy, or obstructive valvular disease~* Participant has started taking hypertensive medications within the past 30 days~* Participant has a known sensitivity to losartan or history of angioneurotic edema

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Losartan potassium 0.1 to 1.4 mg/kg (Type: EXPERIMENTAL): Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
- Losartan potassium 0.3 to 1.4 mg/kg (Type: EXPERIMENTAL): Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
- Losartan potassium 0.7 to 1.4 mg/kg (Type: EXPERIMENTAL): Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Systematic Multi-domain Alzheimer's Risk Reduction Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 70-89 Years of Age~* Fluent in the English Language~* Low-normal performance on a brief telephone cognitive screen, measured using the Cognitive Abilities Screening Instruments (CASI). Low-normal scores are defined as 26-29.~* Has at least two additional risk factors that will be targeted by the intervention.~Exclusion Criteria:~* Residing in a skilled nursing or rehabilitation facility~* Receiving palliative care or hospice services~* Charlson comorbidity index score of greater than 5~* Bipolar illness or schizophrenia~* Current alcohol or drug use disorder~* Receiving chronic opioid therapy~* Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis~* Severe visual or hearing impairment~* Requests not to be contacted or not to have their medical record reviewed for research~* Prior evidence of dementia

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- SMARRT Intervention (Type: ACTIVE_COMPARATOR): The SMARRT intervention team will use a standardized procedure to develop an individualized Alzheimer's risk profile for each participant randomized to the SMARRT intervention arm. Participants will then meet in-person with an interventionist to review their risk profile and develop an initial personalized risk reduction action plan. For the few participants enrolled during COVID, initial interventionist visits were conducted by phone. Targeted areas will include: increasing physical, mental and social activities; quitting smoking; healthy diet; controlling cardiovascular risk factors (diabetes, hypertension), including avoiding hypoglycemia in people with diabetes; reducing depressive symptoms; improving sleep; and decreasing use of potentially harmful medications.
- Health Education Intervention (Type: ACTIVE_COMPARATOR): Participants in the Health Education arm will be mailed general information that will address factors that will be targeted in the SMARRT intervention, including physical, mental and social engagement; management of cardiovascular risk factors; quitting smoking, healthy diet; depression; sleep; and contraindicated medications. HE participants will not be provided with personalized information about their risk of Alzheimer's and dementia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete